VISTAGEN THERAPEUTICS, INC. (VTGN) Free cash flow 2017–2024
VISTAGEN THERAPEUTICS, INC. (VTGN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$25.8MFY2024 · since FY2017: -$7.5M → -$25.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$25.8M | +48.6% |
| FY2023 | -$50.2M | -10.5% |
| FY2022 | -$45.5M | -268.1% |
| FY2021 | -$12.3M | +21.6% |
| FY2020 | -$15.8M | -7.2% |
| FY2019 | -$14.7M | -62.3% |
| FY2018 | -$9.1M | -20.8% |
| FY2017 | -$7.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More VTGN financial trends
VTGN RevenueVTGN Net incomeVTGN Net marginVTGN Gross profitVTGN Gross marginVTGN Operating incomeVTGN Operating marginVTGN Operating cash flowVTGN Capital expendituresVTGN Return on equityVTGN Stock buybacksVTGN Dividends paidVTGN Total assetsVTGN Total liabilitiesVTGN Shareholders’ equityVTGN overview →